Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience

Overview

Journal In Vivo

Specialty Oncology

Date 2023 Jan 2

PMID 36593005

Authors

Sang-Gon Park

Hee Jeong Lee

Seul Bi Lee

Ran Hong

Affiliations

Soon will be listed here.

Abstract

Background/aim: Programmed cell death ligand 1 (PD-L1) is an immune checkpoint protein involved in immune evasion of malignant tumors. Confirmation of PD-L1 expression in non-small cell lung cancer (NSCLC) is necessary for the determination of immunotherapy using immune checkpoint inhibitors (ICIs). PDL-1 expression is currently analyzed by immunohistochemistry and is the only available biomarker that can guide the treatment of NSCLC using ICIs. The present study was conducted to compare the expression of three different commercial clones of PD-L1 in order for immunohistochemistry (IHC) for these clones to become more reliable for surgical pathologists.

Materials And Methods: This study examined the expression of PD-L1 in 76 cases of resected lung cancer using IHC. Three clones were examined: SP263, SP142, and 22C3PharmDx, which are commercially approved for quantifying PD-L1 expression in lung cancer.

Results: Of the 76 patients whose samples were evaluated for PD-L1 using the IHC 22C3pharmDx assay, 19 (25.0%) had a tumor proportion score (TPS) of ≥50% and 41 (53.9%) had a PD-L1 TPS of ≥1%. Furthermore, using the SP263, 48.7% had a TPS of ≥1% and 18.4% of >50%. The SP142 assay was used to evaluate tumor cells (TCs) and immune cells (ICs). Twenty (26.3%) cases were positive for TCs and 25 (32.9%) were reactive for ICs.

Conclusion: These three commercial PD-L1 clones are comparable for detecting primary targets for anti-tumor immunotherapies. Careful evaluation by a pathologist is necessary to minimize misinterpretation errors.

References

Bigelow E, Bever K, Xu H, Yager A, Wu A, Taube J . Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp. 2013; (71). PMC: 3582653. DOI: 10.3791/4059. View

Ribas A, Tumeh P . The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res. 2014; 20(19):4982-4. PMC: 4184978. DOI: 10.1158/1078-0432.CCR-14-0933. View

Badiu D, Zgura A, Mehedintu C, Haineala B, Anghel R, Bacinschi X . The Role of Programmed Cell Death Receptor 1 in Lung Cancer. In Vivo. 2022; 36(2):1007-1012. PMC: 8931921. DOI: 10.21873/invivo.12794. View

Kleponis J, Skelton R, Zheng L . Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med. 2015; 12(3):201-8. PMC: 4607816. DOI: 10.7497/j.issn.2095-3941.2015.0046. View

Kerr K, Nicolson M . Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. Arch Pathol Lab Med. 2016; 140(3):249-54. DOI: 10.5858/arpa.2015-0303-SA. View

Sznol M, Chen L . Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response. Clin Cancer Res. 2013; 19(19):5542. PMC: 6101650. DOI: 10.1158/1078-0432.CCR-13-2234. View

Karachaliou N, Gonzalez Cao M, Teixido C, Viteri S, Morales-Espinosa D, Santarpia M . Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. Cancer Biol Med. 2015; 12(2):79-86. PMC: 4493378. DOI: 10.7497/j.issn.2095-3941.2015.0029. View

Goyal L, Muzumdar M, Zhu A . Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res. 2013; 19(9):2310-8. PMC: 4583193. DOI: 10.1158/1078-0432.CCR-12-2791. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

10.

Brahmer J . Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol. 2013; 31(8):1021-8. DOI: 10.1200/JCO.2012.45.8703. View

11.

Baik C, Rubin E, Forde P, Mehnert J, Collyar D, Butler M . Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. Clin Cancer Res. 2017; 23(17):4992-5002. PMC: 5735832. DOI: 10.1158/1078-0432.CCR-16-3066. View

12.

Sheppard K, Fitz L, Lee J, Benander C, George J, Wooters J . PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004; 574(1-3):37-41. DOI: 10.1016/j.febslet.2004.07.083. View

13.

Berghoff A, Ricken G, Widhalm G, Rajky O, Hainfellner J, Birner P . PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol. 2013; 33(1):42-9. DOI: 10.5414/np300698. View

14.

Lin G, Fan X, Zhu W, Huang C, Zhuang W, Xu H . Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget. 2017; 8(48):83986-83994. PMC: 5663570. DOI: 10.18632/oncotarget.20233. View

15.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

16.

Hirsch F, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K . PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2016; 12(2):208-222. DOI: 10.1016/j.jtho.2016.11.2228. View

17.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

18.

El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492-2502. PMC: 7539326. DOI: 10.1016/S0140-6736(17)31046-2. View

19.

Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomizawa K . Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer. 2016; 98:69-75. DOI: 10.1016/j.lungcan.2016.04.021. View

20.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View